Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov;85(5):1073-1090.
doi: 10.1016/j.jaad.2021.04.080. Epub 2021 Apr 30.

Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis

Joseph R Stoll  1 , Jonathan Willner  1 , Yuna Oh  1 , Melissa Pulitzer  1 , Alison Moskowitz  1 , Steven Horwitz  1 , Patricia Myskowski  1 , Sarah J Noor  2
Affiliations
Review

Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part I: Clinical and histologic features and diagnosis

Joseph R Stoll et al. J Am Acad Dermatol. 2021 Nov.

Abstract

Primary cutaneous T-cell lymphomas (CTCLs) are defined as lymphomas with a T-cell phenotype that present in the skin without evidence of systemic or extracutaneous disease at initial presentation. CTCLs other than mycosis fungoides and Sézary syndrome (SS) account for approximately one third of CTCLs and encompass a heterogenous group of non-Hodgkin lymphomas, ranging from indolent lymphoproliferative disorders to aggressive malignancies with a poor prognosis. The spectrum of CTCLs continues to broaden as new provisional entities are classified. Given the morphologic and histologic overlap among CTCLs and other diagnoses, a thorough clinical history, physical evaluation, and clinicopathologic correlation are essential in the work up and diagnosis of these rare entities. This article will summarize the epidemiologic, clinical, pathologic, and diagnostic features of CTCLs other than mycosis fungoides and SS.

Keywords: CD30(+) lymphoproliferative disorders; Sézary syndrome; T-cell lymphoma; adult T-cell leukemia; adult T-cell lymphoma; angioimmunoblastic T-cell lymphoma; cutaneous T-cell lymphoma; cytotoxic primary cutaneous anaplastic large cell lymphoma; extranodal NK/T-cell lymphoma; lymphomatoid papulosis; mycosis fungoides; nasal type; not otherwise specified; peripheral T-cell lymphoma; primary cutaneous CD4(+) small/medium T-cell lymphoproliferative disorder; primary cutaneous CD8(+) aggressive epidermotropic cytotoxic T-cell lymphoma; primary cutaneous acral CD8(+) T-cell lymphoma; primary cutaneous gamma-delta T-cell lymphoma; subcutaneous panniculitis-like T-cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Noor is on the Advisory Board for Kyowa Kirin. Dr Horowitz is a consultant for Janssen, Kura Oncology, Myeloid Therapeutics, Vividion Therapeutics, and C4 Therapeutics; a Principal Investigator for Daiichi Sankyo, Portola Pharmaceuticals, Forty Seven Inc, Trillium Therapeutics, and Aileron; and a Principal Investigator and consultant for Kyowa Kirin, Celgene, Seattle Genetics, Verastem, Takeda, and ADC Therapeutics. Dr Moskowitz is a consultant for Imbrium Therapeutics LP; a Principal Investigator for Miragen, Incyte, Bristol-Myers Squibb; and a Principal Investigator and consultant for Merck and Seattle Genetics. Authors Stoll and Oh and Drs Pulitzer, Willner, and Myskowski have no conflicts of interests to declare.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles
-